In terms of AML patients, there were 12 patients, including 3 cases of relapse or refractory (two of them did not carry out remission treated with venetoclax and azacitidine) and 9 cases in initial treatment (one case carrying FLT3‐ITD mutation, one case carrying DMNT3A mutation), sensitive to the combination of abivertinib and venetoclax. The gene discussed is FLT3; the disease is acute myeloid leukemia.